Proteome Sciences Share Discussion Threads

[mashman] 24/3/2021 18:48

Tom it was one short c&p on LSE and a link hardy spamming. I agree that the LSE BB is rather bad.

[1xtrader] 24/3/2021 14:43

Good man look after yourself Tom

[tom barnaby] 24/3/2021 14:37

All good thanks 1xtrader.

A very enjoyable Egg mayonnaise, cheese and tomato sandwich (homemade) with a packet of crisps for luncheon today.

[1xtrader] 24/3/2021 14:31

Tom are you ok today you seem like something is bothering you

[tom barnaby] 24/3/2021 14:25

I'm note sure, 1xtrader.

I hope that helps.

[1xtrader] 24/3/2021 14:19

What did he say Tom

[tom barnaby] 24/3/2021 12:45

Avatars will have noted there is some complete and utter end going by the avatar "hycol" posting boring C&Ps over on the horrendous LSE BB.

[1xtrader] 23/3/2021 20:36

https://www.drugtargetreview.com/news/86894/zinc-finger-gene-therapy-could-help-to-treat-alzheimers-disease/

[tom barnaby] 23/3/2021 20:34

Yes, they won’t.


I hope that helps.

[1xtrader] 23/3/2021 20:31

Oxford biodynamicVulpes Life Sciences Fund has 12%Does anyone know if Proteome Science will benefit from recent news

[tom barnaby] 23/3/2021 19:44

I note there has been further activity on the appreciation front today.

[elpirata] 23/3/2021 10:09

I note theres still legs in a covid (test) rns as shown by OBD today, of course PRM dont have any tests & just provide TMT/biomarker testing services to those who have the IP (or academia)

[tom barnaby] 23/3/2021 08:18

I note that 3 avatars like 1xtraders post 58661 but no one at all has an opinion of the avatar monte1's 58662.

[monte1] 22/3/2021 11:02

I suppose it all depends on your definition of good. If your definition of ‘good’ is ‘not really very good’ then you are spot on 1xtrader.

[1xtrader] 22/3/2021 10:59

Company has fundingCompany has good products Company has good revenue Company has good projects Company has good patents Company has bad share priceIt can all change quickly we all know the risks

[wasjobber] 22/3/2021 10:44

I'm told CJP would be a very foolish man if he did that.

[tom barnaby] 22/3/2021 10:29

A simple link would do for those dull enough to find it interesting. For everyone else it is clutter.

[stocktastic] 22/3/2021 10:27

Colin
Great posts.
Ignore the attention seekers that are too dim to read them and shout them down in some bizarre, 'scared' fashion, just in case they could be misinterpreted as rampy

The posts are totally relevant.

[tom barnaby] 22/3/2021 10:26

Quite so. However, if he calls it in they are potentially left with nothing at all, not even peanuts.

[stocktastic] 22/3/2021 10:23

1xtrader

Increased use of TMT is all good, but PRM will only see proper gains if the uplift is steps higher

You say £10M is peanuts - peanuts is what shareholders will be left with, if the CEO converts his loan

[colinhy] 21/3/2021 21:57

Proteome Sciences TMT technology features in the following research published March 15 2021.

I note that the Oxford AstraZeneca Covid19 vaccine creators Sarah Gilbert and Susan Morris at the Oxford univerisity Jenner Institute are among the authors.


"SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription."


Background
ChAdOx1 nCoV-19 is a recombinant adenovirus vaccine against SARS-CoV-2 that has passed phase III clinical trials and is now in use across the globe. Although replication-defective in normal cells, 28 kbp of adenovirus genes is delivered to the cell nucleus alongside the SARS-CoV-2 S glycoprotein gene.

Methods
We used direct RNA sequencing to analyse transcript expression from the ChAdOx1 nCoV-19 genome in human MRC-5 and A549 cell lines that are non-permissive for vector replication alongside the replication permissive cell line, HEK293. In addition, we used quantitative proteomics to study over time the proteome and phosphoproteome of A549 and MRC5 cells infected with the ChAdOx1 nCoV-19 vaccine.

Total and phosphoproteome analysis
Aliquots of 100 μg of each sample were digested with trypsin (2.5 μg trypsin per 100 μg protein; 37 °C, overnight) and labelled with Tandem Mass Tag (TMT) ten plex reagents according to the manufacturer’s protocol (Thermo Fisher Scientific, Loughborough, LE11 5RG, UK), and the labelled samples pooled according to cell line.

For the phosphoproteome analysis, the remainder of the TMT-labelled pooled sample was also desalted using a SepPak cartridge (Waters, Milford, MA, USA). Eluate from the SepPak cartridge was evaporated to dryness and subjected to TiO2-based phosphopeptide enrichment according to the manufacturer’s instructions (Pierce).

Conclusions
Our analyses provide valuable insight into the transcriptomic and proteomic repertoire of an important vaccine, providing confirmation that the vaccine vector’s transcriptome is essentially as intended in these cell lines. However, care should be taken when extrapolating the results of the transcriptomic analysis using single cell types to the complex multicellular differentiated cell-rich environment these types of vaccines encounter when they are administered (by whatever route). Recently, an in-depth multi-omic analysis of the herpes virus genome revealed that an oncolytic herpes virus licenced in 2015 under the name Imlygic is in fact deleted for an additional third gene rather than the two intended because of a previously unknown ORF present in the deleted region [49]. Whilst there is no suggestion that this has been a problem, it highlights the importance of utilising state-of-the-art and unbiased approaches to survey genetically modified viruses intended for clinical use. Finally, we argue that this kind of analysis is relatively straightforward and should be routinely incorporated into the early stages of future viral vector evaluation pipelines to allow a robust understanding of the transcriptomic potential of engineered viral vectors.




===============================
for info
How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine

[tom barnaby] 21/3/2021 21:24

BOL!

Look at the rubbish the avatar has been cutting and pasting for years and save yourself the bother of reading the reply.

[dk37] 21/3/2021 21:03

colinhy

Thank you for your response. Can i assume, given your post , that you believe this new development may be of some significance for prm over the near term.